SHANGHAI

上海

,

，

June 5, 2025

2025年6月5日

/PRNewswire/ -- The 2025 ASCO Annual Meeting successfully concluded in

/PRNewswire/ -- 2025年ASCO年会成功落幕在

Chicago

芝加哥

on

开启

June 3

6月3日

(

(

local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global experts..

当地时间），恒瑞医药展现了强大的国际影响力，共展示15款创新药物和72项研究成果，包括4项口头报告、5项快速口头报告、27项壁报展示以及36项在线发表。多项突破性研究成果引发全球专家广泛讨论。

In the field of breast cancer, results from 19 studies evaluating the company's innovative drugs—pyrotinib, dalpiciclib, camrelizumab, apatinib, adebrelimab, Trastuzumab rezetecan (SHR-A1811

在乳腺癌领域，评估该公司创新药物（吡咯替尼、达匹西利、卡瑞利珠单抗、阿帕替尼、阿得贝利单抗、Trastuzumab rezetecan（SHR-A1811））的19项研究结果

),

),

and SHR-2017, either in combination with each other or with chemotherapies, were presented at ASCO 2025. Notably, 7 studies involving pyrotinib and 6 studies involving dalpiciclib were selected, with both agents consistently demonstrating promising efficacy, reinforcing their established roles in breast cancer treatment. Furthermore, studies evaluating SHR-A1811 and adebrelimab were selected for rapid oral presentations, attracting considerable attention from the industry..

SHR-2017与彼此联合或与化疗联合的研究在2025年ASCO会议上展示。值得注意的是，涉及吡咯替尼的7项研究和涉及达匹西利的6项研究被选中，这两种药物均持续显示出良好的疗效，进一步巩固了它们在乳腺癌治疗中的地位。此外，评估SHR-A1811和阿得贝利单抗的研究入选了快速口头报告，引起了业界的广泛关注。

In the field of gastrointestinal cancers, drugs such as camrelizumab, apatinib, adebrelimab, and SHR-8068 were featured in a total of 30 accepted studies. Notably, camrelizumab was included in 21 of these studies, demonstrating its broad therapeutic profile and potential while reinforcing its position as a key focus at ASCO.

在消化道肿瘤领域，卡瑞利珠单抗、阿帕替尼、阿得贝利单抗以及SHR-8068等药物共有30项研究入选，其中卡瑞利珠单抗参与的研究多达21项，展现了其广泛的治疗特性和潜力，进一步巩固了其作为ASCO焦点的重要地位。

This further solidifies the achievements of .

这进一步巩固了的成果。

China

中国

-developed PD-1 inhibitors on the global stage. Additionally, adebrelimab, which has achieved significant breakthroughs in lung cancer in recent years, is actively expanding into new indications. At this year's ASCO, five related studies exploring adebrelimab's efficacy in indications such as hepatocellular carcinoma .

-在全球舞台上开发了PD-1抑制剂。此外，近年来在肺癌领域取得显著突破的阿德布雷利单抗（adebrelimab）正在积极拓展新的适应症。在今年的ASCO会议上，有五项相关研究探索了阿德布雷利单抗在肝细胞癌等适应症中的疗效。

(

(

HCC

肝细胞癌

),

),

cholangiocarcinoma

胆管癌

(

(

CCA

CCA

) ,

) ，

and pancreatic cancer were presented. The ongoing emergence of cutting-edge research on both established and emerging agents holds promise for improving clinical outcomes for patients with gastrointestinal tumors.

和胰腺癌的研究结果被公布。关于已确立的和新兴药物的前沿研究不断涌现，为改善胃肠道肿瘤患者的临床结果带来了希望。

Across a wide range of disease areas—including lung cancer, gynecologic cancers, lymphoma, bladder cancer, head and neck cancer, melanoma, sarcoma, nasopharyngeal carcinoma, chordoma, salivary gland cancer, thymic cancer, desmoid tumors, and salivary duct carcinoma—Hengrui Pharma's innovative oncology portfolio (camrelizumab, apatinib, adebrelimab, pyrotinib, dalpiciclib, fluzoparib, famitinib, SHR-A1811, SHR-1501, SHR-1701, SHR-1826, SHR-A1912, and SHR-A2102) was featured in 22 research presentations at ASCO 2025.

横跨多个疾病领域——包括肺癌、妇科癌症、淋巴瘤、膀胱癌、头颈癌、黑色素瘤、肉瘤、鼻咽癌、脊索瘤、唾液腺癌、胸腺癌、硬纤维瘤和唾液导管癌——恒瑞医药的创新肿瘤产品组合（卡瑞利珠单抗、阿帕替尼、阿得贝利单抗、吡咯替尼、达尔西利、氟唑帕利、法米替尼、SHR-A1811、SHR-1501、SHR-1701、SHR-1826、SHR-A1912 和 SHR-A2102）在2025年ASCO大会上进行了22项研究报告展示。

These comprised 4 oral presentations, 2 rapid oral presentations, 12 poster presentations, and 4 online publications, collectively demonstrating the company's robust R&D capabilities. Additionally, one online publication highlighted ondansetron oral soluble film, underscoring its favorable efficacy in preventing and treating chemotherapy-induced nausea and vomiting (CINV)..

这些成果包括4项口头报告、2项快速口头报告、12项海报展示和4篇在线发表文章，共同展示了该公司强大的研发实力。此外，一篇在线发表的文章重点介绍了昂丹司琼口腔溶膜，强调了其在预防和治疗化疗引起的恶心呕吐（CINV）方面的良好疗效。

For 15 consecutive years, Hengrui Pharma has consistently presented its cutting-edge research at the ASCO Annual Meeting, highlighting the company's global leadership in oncology drug research and development while showcasing

连续15年，恒瑞医药在ASCO年会上不断展示其前沿研究成果，彰显了公司在肿瘤药物研发领域的全球领导地位，同时展示了

China's

中国的

robust pharmaceutical innovation capabilities to the international academic community. The inclusion of 70 Hengrui-sponsored studies at this year's meeting reflects the strong foundation laid by the company's portfolio of 23 marketed innovative drugs and a robust pipeline of over 90 candidates currently in development.

强大的医药创新能力展示给国际学术界。在今年的会议上，恒瑞赞助的70项研究入选，反映了公司已上市的23款创新药物和目前在研的90多个候选药物的强大基础。

Looking ahead, Hengrui will remain committed to its patient-centric approach, striving to develop advanced therapeutics that support the 'Healthy China' initiative and enhance clinical outcomes for patients globally..

展望未来，恒瑞将继续坚持“以患者为中心”的理念，努力开发支持“健康中国”战略的先进疗法，提高全球患者的临床治疗效果。

SOURCE Hengrui Pharma

来源：恒瑞医药

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

是否在PRNEWSWIRE.COM上展示？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用